Adverse events PFMT + Anal EStim versus PFMT alone · Patients with postprostatectomy UI
Treatment of UI after radical: one active treatment showed no clear difference in adverse events PFMT + Anal EStim versus PFMT alone compared with another active treatment (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events Adverse event episodes (n) reported · patients with treating osteoarthritis
The intervention probably leads to lower adverse events Adverse event episodes (n) reported (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events Adverse event episodes (n) reported · patients with treating osteoarthritis
The intervention showed no clear difference in adverse events Adverse event episodes (n) reported (moderate certainty).
1 finding from 1 review
Intervention not reported
Numbers of adverse events due to access thrombosis · patients with the anaemia of end‐stage kidney disease undergoing dialysis
The intervention showed no clear difference in numbers of adverse events due to access thrombosis (high certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy showed no clear difference in adverse events (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Proportion of infants with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of infants with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Proportion of mothers with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of mothers with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Intervention not reported
Discontinuation of study drug due to adverse events · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention probably leads to lower discontinuation of study drug due to adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Discontinuation of study drug due to adverse events · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ death in past 12 months (RR > 1 denotes higher risk of death) · adult patients with harmful or hazardous alcohol or substance use
It is very uncertain whether lay health worker‐led interventions for adult patients with harmful… changes adverse events ‐ deaths (RR < 1 denotes lower risk) compared with enhanced usual care (very low certainty).
1 finding from 1 review
Adverse events requiring (or indicated for) surgery · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
It is very uncertain whether active exercise regimen changes adverse events requiring (or indicated for) surgery compared with an immobilisation regimen following surgery (very low certainty).
1 finding from 1 review
Adverse events requiring (or indicated for) surgery · participants undergoing rehabilitation following surgery for flexor tendon injuries of the handa
It is very uncertain whether place and hold exercise regimen changes adverse events requiring (or indicated for) surgery compared with controlled passive exercise regimen following surgery (very low certainty).
1 finding from 1 review
Number experiencing adverse effects · the management of chronic obstructive pulmonary disease
It is very uncertain whether multi‐component intervention changes adverse events: number of people experiencing an AE compared with other intervention or routine, usual care or control treatment (very low certainty).
1 finding from 1 review
Specific adverse events: haemorrhage · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: need for reoperation/ reimplantation · adults with chronic pain
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events: need for reoperation/ reimplantation · adults with chronic pain
The review found no eligible studies for this question.
2 findings from 1 review
Adverse events: bronchospasm/treatment discontinued · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: bronchospasm/treatment discontinued compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Medical adverse events up to 2 months after surgery · people with age‐related cataract
Routine preoperative medical testing showed no clear difference in medical adverse events up to 2 months after surgery compared with selective or no testing (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · women with heavy menstrual bleeding
It is very uncertain whether antifibrinolytics changes withdrawal from treatment because of adverse events compared with ethamsylate (very low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review